Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Equity (Deficit)

v3.10.0.1
Consolidated Statements of Equity (Deficit) - USD ($)
$ in Thousands
Total
Series B Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Noncontrolling Interest [Member]
Balance at Dec. 31, 2016 $ 2,261 $ 0 $ 4 $ 175,887 $ (172,034) $ (1,596)
Balance (in shares) at Dec. 31, 2016   0 3,345,466      
Stock-based compensation 3,409 $ 0 $ 0 3,409 0 0
Stock issued under "at-the-market" offering 6,346 $ 0 $ 0 6,346 0 0
Stock issued under "at-the-market" offering (in shares)   0 313,583      
Stock issued for exercise of stock options $ 166 $ 0 $ 0 166 0 0
Stock issued for exercise of stock options (in shares) 11,965 0 11,965      
Series A preferred stock issue costs $ (27) $ 0 $ 0 (27) 0 0
Series A preferred stock dividends (73) 0 0 0 (73) 0
Series A and B preferred stock beneficial conversion feature discount 0 0 0 6,889 (6,889) 0
Net Loss (15,174) 0 0 0 (15,174) 0
Non-controlling interest (318) 0 0 0 0 (318)
Balance at Dec. 31, 2017 (3,410) $ 0 $ 4 192,670 (194,170) (1,914)
Balance (in shares) at Dec. 31, 2017   0 3,671,014      
Stock-based compensation 2,074 $ 0 $ 0 2,074 0 0
Stock issued under "at-the-market" offering 12,172 $ 0 $ 3 12,169 0 0
Stock issued under "at-the-market" offering (in shares)   0 3,534,982      
Common stock and warrants issued to vendors 35 $ 0 $ 0 35 0 0
Common stock and warrants issued to vendors (in Shares)   0 50,000      
Series A preferred stock dividends (243) $ 0 $ 0 0 (243) 0
Series A and B preferred stock beneficial conversion feature discount 0 9,161 0 0 (9,161) 0
Issuance of Common Stock, preferred Stock and Warrants in Units Offering, net of issuance costs 16,916 $ 641 $ 2 16,273 0 0
Issuance of Common Stock, preferred Stock and Warrants in Units Offering, net of issuance costs (in shares)   15,723 2,520,000      
Issuance of SYN Biomics Stock 36 $ 0 $ 0 977 0 (941)
Conversion of Series B Preferred Stock to Common 0 $ (4,042) $ 6 6,556 (2,520) 0
Conversion of Series B Preferred Stock to Common (in shares)   (6,562) 5,706,087      
Net Loss (13,367) $ 0 $ 0 0 (13,367) 0
Non-controlling interest (54) 0 0 0 0 (54)
Balance at Dec. 31, 2018 $ 14,159 $ 5,760 $ 15 $ 230,754 $ (219,461) $ (2,909)
Balance (in shares) at Dec. 31, 2018   9,161 15,482,083